AIX-EN-PROVENCE, FRANCE--(Marketwired - Sep 9, 2015) - SuperSonic Imagine (
"The integration of the XC6-1 probe into the Aixplorer platform is vivid proof of our ongoing commitment to leadership in ultrasound innovation. The single crystal technology improves upon its predecessor's image clarity from near field down through deep structures with a level of detail never seen before," commented Tom Egelund, President and Chief Executive Officer of SuperSonic Imagine.
The XC6-1 probe provides advanced imaging capabilities for a variety of exams including abdominal and pelvic assessments, which represent the majority of ultrasound exams performed. A key feature of the XC6-1 is its ability to greatly enhance spatial and contrast resolution. The probe's single crystal technology allows deeper penetration and higher efficiency even in the most technically challenging patients.
The Aixplorer ultrasound system includes SuperSonic Imagine's patented ShearWave™ Elastography which provides physicians the ability to assess and quantify tissue stiffness in real-time. A color-coded map of tissue elasticity is displayed in conjunction with the two-dimensional ultrasound image, providing physicians a complete and accurate stiffness evaluation easily and quickly. Tissue stiffness is used by physicians to help identify potentially malignant or other diseased tissue. The ShearWave Elastography imaging technology has been further optimized on the new XC6-1 probe. The improvements build on the Company's innovation expertise as the pioneers of ShearWave, helping physicians to better assess tissue-related pathologies including chronic liver disease.
SuperSonic Imagine is also pleased to announce additional upgrades to the Aixplorer System. In addition to conducting a full re-optimization of all imaging modes and making overall improvements to the ShearWave imaging, the Company added a new reporting tool, which automatically calculates relevant stiffness parameters to easily evaluate stages of liver fibrosis. The enhanced Aixplorer offers a more intuitive user experience. These enhancements combined with the new XC6-1 probe, enable increased efficiency, streamlined workflow and reduction of exam duration.
"The image quality of the new probe is exceptional: the contrast resolution allows lesion detection even in heavy patients. The ability to see both near and far field in real-time provides increased diagnostic confidence in a quick, simple exam. These technological advances will significantly improve the management of my patients with chronic liver disease and other abdominal clinical applications which are a significant part of my daily practice," explains Dr. Alfredo Goddi, Radiologist, and Chief Medical Officer of the medical center SME-Diagnostica per Immagini in Varese, Italy.
About SuperSonic Imagine Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer ® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer ® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.
For more information about SuperSonic Imagine, please go to www.supersonicimagine.com
SuperSonic Imagine Marketing & Communication Emmanuelle Vella Email Contact +33 4 86 79 03 27 NewCap Investor Relations - EU Pierre Laurent / Florent Alba Email Contact +33 1 44 71 98 55 Blueprint Life Science Group Investor Relations - US Candice Knoll Email Contact +1 415 375 3340 Ext. 4 ComCorp Media Relations Adelaide Manester Email Contact +33 1 58 18 32 58
